Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study

Trial Profile

Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Wuzhong Pharmaceutical Group
  • Most Recent Events

    • 12 Apr 2017 Status changed from recruiting to completed.
    • 25 Jan 2017 Planned number of patients changed from 540 to 560.
    • 24 Jan 2017 Planned End Date changed from 31 Aug 2014 to 31 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top